Delpha Capital Management’s Halozyme HALO Stock Holding History

Delpha Capital Management’s Portfolio HALO Stock Details HALO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-2,154	Closed	-$44K	–	578
2017 Q4	$44K	Buy	+2,154	New	+$39.6K	0.05%	367

Other funds holding HALO

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Delpha Capital Management's HALO Position: Q1 2018 in Review

Delpha Capital Management sold out of Halozyme (HALO) in Q1 2018, closing a stake of 2,154 shares — an estimated $44K sold.

Delpha Capital Management first reported a position in HALO in Q4 2017 and held it in 1 quarter. The position peaked at $44K in Q4 2017. 209 funds tracked by Wall St. Rank hold HALO as of Q1 2018.

Delpha Capital Management reported no remaining Halozyme position as of Q1 2018 after selling out during the quarter.
Delpha Capital Management sold 2,154 Halozyme shares in Q1 2018, an estimated $44K.
Delpha Capital Management first reported a position in Halozyme in Q4 2017 and held it in 1 quarter.
Delpha Capital Management's Halozyme position peaked at $44K in Q4 2017.
209 funds tracked by Wall St. Rank held Halozyme as of Q1 2018.

Based on Delpha Capital Management's 13F filing for Q1 2018, filed 11 May 2018.